ReviewMedicine international
Artificial intelligence in oncology: Current status and possibilities (Review).
Review in Medicine international. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential and mechanisms of rehabilitation interventions in preventing cancer metastasis.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is increasingly reshaping oncology by enhancing diagnostic accuracy, improving prognostication and enabling personalized treatment planning. The present review aimed to critically synthesize the contemporary landscape of AI applications across cancer imaging, digital pathology, clinical outcome prediction, chemotherapy and radiotherapy. Recent advances in machine learning and deep learning, particularly convolutional neural networks and transformer-based architectures, have demonstrated robust performance in lesion detection, tumour grading, survival prediction and treatment optimization, in several instances approaching or exceeding expert-level accuracy. Despite these advances, translation into routine clinical practice remains limited due to dataset bias, limited generalizability, the lack of standardized data protocols, insufficient interpretability and regulatory barriers. Ethical challenges related to fairness, transparency and equitable access are especially relevant in low- and middle-income countries. Emerging frontiers, including multimodal AI, foundation models, federated learning, and explainable AI, provide potential solutions to these challenges. Multidisciplinary collaboration, rigorous prospective validation and robust ethical governance will be essential to realize the full potential of AI in advancing precision oncology and improving global cancer outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.